Dimerix’s ACTION3 Study Set for March 2026 Blinded Statistical Check
Dimerix Limited is set to conduct a blinded statistical review of its pivotal Phase 3 ACTION3 study in March 2026, aiming to confirm the trial remains powered to demonstrate the primary endpoint of proteinuria reduction in FSGS patients.
- Blinded review scheduled for late March 2026 to confirm statistical assumptions
- ACTION3 Phase 3 study previously cleared futility and safety reviews
- Primary endpoint focuses on proteinuria reduction, accepted by FDA
- Results of blinded review expected in April 2026
- DMX-200 targets FSGS, a rare kidney disease with high unmet need
Context of the ACTION3 Study
Dimerix Limited, an Australian biopharmaceutical company, is advancing its Phase 3 clinical trial, ACTION3, which investigates DMX-200, a novel treatment for focal segmental glomerulosclerosis (FSGS). FSGS is a rare and serious kidney disorder characterised by progressive scarring of the kidney’s filtering units, leading to proteinuria and eventual kidney failure. The trial is designed to evaluate the efficacy and safety of DMX-200 in reducing proteinuria, a key marker of kidney damage, alongside secondary measures of kidney function.
Significance of the Blinded Statistical Review
In late March 2026, Dimerix will conduct a blinded review of the ACTION3 data to verify that the study’s statistical assumptions remain valid. This process, carried out without knowledge of treatment assignments, ensures the trial is still adequately powered to detect a meaningful treatment effect on the primary endpoint. The review follows a series of positive milestones, including a formal futility analysis in March 2024 and seven independent safety reviews, all of which reported no safety concerns or protocol changes.
Regulatory and Clinical Implications
The FDA has previously endorsed the primary endpoint of percent reduction in proteinuria as suitable for traditional approval of DMX-200 under the 505(b)(1) regulatory pathway, with kidney function changes as a secondary endpoint. Confirming the statistical assumptions through this blinded review is a critical step in maintaining the trial’s integrity and bolstering confidence that the study can meet its objectives. Positive results would support Dimerix’s path toward regulatory approval and eventual market entry.
Broader Impact and Future Outlook
With limited treatment options currently approved for FSGS, DMX-200 represents a promising candidate addressing a significant unmet medical need. The company’s CEO, Dr Nina Webster, emphasised the evolving landscape of FSGS treatment and the importance of ensuring the trial remains robust and well-powered. The blinded review’s outcome, expected in April 2026, will be closely watched by investors and the medical community alike as a key indicator of the trial’s trajectory and potential commercial success.
Overall, this step reflects Dimerix’s disciplined approach to clinical development and regulatory engagement, reinforcing its commitment to delivering value for patients and shareholders.
Bottom Line?
The upcoming blinded review will be a pivotal moment, potentially shaping the future of DMX-200 and Dimerix’s role in FSGS treatment.
Questions in the middle?
- Will the blinded review confirm the trial’s statistical power to meet the primary endpoint?
- How might evolving FSGS treatment standards impact the trial’s design or outcomes?
- What are the next regulatory milestones following the blinded review results?
